AnPac Bio Announces Receipt of the First Payment from a Malaysia Customer On a Signed US$1.5 Million Cancer Detection Equipment Purchase Contract

NEW YORK, March 7, 2023 /PRNewswire/ – AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio" or the "Company" (Nasdaq: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced today that it has received the first payment in late February 2023 from a Malaysian customer who had signed a US$1.5 million purchase contract for AnPac Bio's Model AP9080 cancer detection devices. The Model AP9080 cancer detection device is based on Company's patented, novel multi-cancer testing technology named Cancer Differentiation Analysis Technology (CDA). As the first major sale of the Company's cancer detection device into the Southeast Asia region, this is truly a milestone for the Company. It also signifies that the Company has formally entered the global cancer detection equipment market, as well as confirmation of AnPac Bio's novel technology, reputation, and its capability to penetrate into the vast global market.      

Read more at prnewswire.com